SIM0417 clinical trials
Also written SIM0417.
How each study uses SIM0417 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2022 (7)
| Year | Studies |
|---|---|
| 2022 | 7 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses SIM0417 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- To Evaluate SSD8432/ Ritonavir in Adults With COVID-19CompletedPhase 1/2Jiangsu Simcere Pharmaceutical Co., Ltd.NCT05369676Written as SSD8432 dose 1/Ritonavir
- A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19CompletedPhase 2/3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT05506176Written as SIM0417
- Safety and Pharmacokinetics of SIM0417 Combined With Ritonavir in Healthy Elderly SubjectsStatus unknownPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT05826249Written as SIM0417/Ritonavir
- Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With RitonavirStatus unknownPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT05731804Written as SIM0417 600 mg; Ritonavir100 mg
- Drug-Drug Interaction Study of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy ParticipantsCompletedPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT05665647Written as Cohort 1: SIM0417/ritonavir and itraconazole
- Study to Investigate the Mass Balance and Biotransformation of SIM0417 in Healthy Adult Chinese Male ParticipantsCompletedPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT05475834Written as SIM0417
- Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical StudyStatus unknownPhase 2Jiangsu Simcere Pharmaceutical Co., Ltd.NCT05373446Written as SSD8432 300mg
- To Evaluate SSD8432/Ritonavir in Adults With COVID-19Status unknownPhase 2/3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT05373433Written as SSD8432 750mg
- A Phase I Clinical Study of SSD8432 in Healthy Adult SubjectsStatus unknownPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT05339646Written as SSD8432 dose 1~7 and Ritonavir